60
Participants
Start Date
September 19, 2012
Primary Completion Date
April 5, 2014
Study Completion Date
April 5, 2014
GSK1120212
GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
GSK Investigational Site, San Antonio
GSK Investigational Site, Salt Lake City
Lead Sponsor
GlaxoSmithKline
INDUSTRY